XML 144 R127.htm IDEA: XBRL DOCUMENT v3.24.0.1
Quarterly Financial Data (Unaudited) - Summary of Restatement of Certain Line Items in the Income Statement (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Quarterly Financial Information [Line Items]                  
Other asset impairments, restructuring and other items $ 57 $ 108 $ 110 $ 217 $ 31 $ 137 $ 718 [1] $ 512 [1] $ 341 [1]
Operating income (loss) 344 (654) (13) (940) 424 (967) 433 [1] (2,197) [1] 1,716 [1]
Income (loss) before income taxes 64 (923) (272) (1,185) 171 (1,178) (624) [1],[2] (3,163) [1],[2] 658 [1],[2]
Income taxes (benefit) (12) (16) (19) 149 107 (900) (7) [2] (643) [2] 211 [2]
Net income (loss) 78 (905) (253) (1,333) 63 (278) (615) (2,499) 456
Net income (loss) attributable to Teva $ 70 $ (871) $ (220) $ (1,301) $ 61 $ (251) $ (559) $ (2,446) $ 417
Earnings (loss) per share attributable to ordinary shareholders:                  
Basic $ 0.06 $ (0.78) $ (0.2) $ (1.17) $ 0.05 $ (0.23) $ (0.5) $ (2.2) $ 0.38
Diluted $ 0.06 $ (0.78) $ (0.2) $ (1.17) $ 0.05 $ (0.23) $ (0.5) $ (2.2) $ 0.38
As previously reported [Member]                  
Quarterly Financial Information [Line Items]                  
Other asset impairments, restructuring and other items $ 46 $ 100 $ 96 $ 132 $ 36 $ 118   $ 414  
Operating income (loss) 355 (646) 2 (855) 419 (949)   (2,099)  
Income (loss) before income taxes 75 (914) (258) (1,100) 166 (1,160)   (3,065)  
Income taxes (benefit) (12) (16) (19) 154 107 (900)   (638)  
Net income (loss) 88 (898) (238) (1,254) 58 (259)   (2,406)  
Net income (loss) attributable to Teva $ 80 $ (863) $ (205) $ (1,221) $ 56 $ (232)   $ (2,353)  
Earnings (loss) per share attributable to ordinary shareholders:                  
Basic $ 0.07 $ (0.77) $ (0.18) $ (1.1) $ 0.05 $ (0.21)   $ (2.12)  
Diluted $ 0.07 $ (0.77) $ (0.18) $ (1.1) $ 0.05 $ (0.21)   $ (2.12)  
Adjustment [Member]                  
Quarterly Financial Information [Line Items]                  
Other asset impairments, restructuring and other items $ 11 $ 8 $ 15 $ 85 $ (5) $ 18   $ 98  
Operating income (loss) (11) (8) (15) (85) 5 (18)   (98)  
Income (loss) before income taxes (11) (8) (15) (85) 5 (18)   (98)  
Income taxes (benefit)       (5)       (5)  
Net income (loss) (11) (8) (15) (80) 5 (18)   (93)  
Net income (loss) attributable to Teva $ (11) $ (8) $ (15) $ (80) $ 5 $ (18)   $ (93)  
Earnings (loss) per share attributable to ordinary shareholders:                  
Basic $ (0.01) $ (0.01) $ (0.02) $ (0.07) $ 0 $ (0.02)   $ (0.08)  
Diluted $ (0.01) $ (0.01) $ (0.02) $ (0.07) $ 0 $ (0.02)   $ (0.08)  
[1] The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.
[2] The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.